Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Heartbeam Inc (BEAT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: BEAT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.62
1 Year Target Price $4.62
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.7% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.29M USD | Price to earnings Ratio - | 1Y Target Price 4.62 |
Price to earnings Ratio - | 1Y Target Price 4.62 | ||
Volume (30-day avg) 2 | Beta -0.79 | 52 Weeks Range 0.54 - 4.00 | Updated Date 01/9/2026 |
52 Weeks Range 0.54 - 4.00 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.66 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -272.38% | Return on Equity (TTM) -792.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 79430808 | Price to Sales(TTM) - |
Enterprise Value 79430808 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.99 | Shares Outstanding 34443563 | Shares Floating 27250714 |
Shares Outstanding 34443563 | Shares Floating 27250714 | ||
Percent Insiders 23.54 | Percent Institutions 9.71 |
Upturn AI SWOT
Heartbeam Inc
Company Overview
History and Background
HeartBeam Inc. (NASDAQ: BEAT) is a pre-revenue medical technology company focused on developing a platform for the early detection of cardiovascular disease. Founded in 2014, the company has been dedicated to creating a non-invasive, AI-powered diagnostic solution that aims to significantly improve the accuracy and speed of cardiac event diagnosis. Significant milestones include the development of its core technology, clinical trial progress, and its public listing on NASDAQ.
Core Business Areas
- Cardiovascular Diagnostics Platform: HeartBeam Inc. is developing a proprietary, AI-driven diagnostic platform designed for the early and accurate detection of acute cardiac conditions, particularly myocardial infarction (heart attack). The platform utilizes advanced signal processing and machine learning algorithms to analyze electrocardiogram (ECG) data.
Leadership and Structure
HeartBeam Inc. is led by a management team with expertise in medical devices, cardiology, and technology. The exact organizational structure and specific names of key leadership personnel can be found in their official filings with the SEC and on their investor relations website.
Top Products and Market Share
Key Offerings
- Description: The core offering is an AI-powered diagnostic platform that aims to provide rapid, accurate, and non-invasive detection of acute cardiac events by analyzing ECG data. The platform is designed to be used in emergency departments and other clinical settings to assist healthcare professionals in diagnosis. Competitors include traditional ECG manufacturers and other companies developing AI-based diagnostic tools in cardiology.
- Product Name 1: HeartBeam Platform (AI-Powered ECG Analysis)
Market Dynamics
Industry Overview
The cardiovascular disease diagnostics market is substantial and growing, driven by an aging global population, increasing prevalence of cardiovascular conditions, and advancements in medical technology. The demand for faster, more accurate, and less invasive diagnostic solutions is a key trend.
Positioning
HeartBeam Inc. aims to position itself as a disruptive force in cardiac diagnostics by leveraging AI to enhance the accuracy and efficiency of ECG interpretation, potentially reducing misdiagnosis rates and improving patient outcomes. Its competitive advantage lies in its proprietary AI algorithms and its focus on early detection of acute events.
Total Addressable Market (TAM)
The TAM for cardiac diagnostics is estimated to be in the tens of billions of dollars globally, encompassing various diagnostic tools and services. HeartBeam Inc. is positioned to capture a segment of this market by offering a novel, AI-driven solution for acute cardiac event detection.
Upturn SWOT Analysis
Strengths
- Proprietary AI-driven technology for ECG analysis
- Focus on early and accurate detection of critical cardiac events
- Potential for improved patient outcomes and reduced healthcare costs
- Experienced management team (to be verified through official sources)
Weaknesses
- Pre-revenue company with no current product sales
- Reliance on future regulatory approvals (e.g., FDA)
- Significant funding requirements for R&D, clinical trials, and commercialization
- Market adoption challenges for new diagnostic technologies
Opportunities
- Growing market demand for advanced cardiovascular diagnostics
- Advancements in AI and machine learning offering enhanced capabilities
- Potential partnerships with healthcare providers and medical device companies
- Expansion into broader cardiac monitoring and diagnostic applications
Threats
- Competition from established medical device companies and innovative startups
- Delays or failure in obtaining regulatory approvals
- Challenges in clinical validation and widespread adoption
- Changes in healthcare reimbursement policies
- Technological obsolescence if not continuously innovated
Competitors and Market Share
Key Competitors
- Philips Healthcare (PHG)
- GE Healthcare (GEHC)
- CardioNet (now BioTelemetry, acquired by Philips)
- Hill-Rom (now Baxter International - BAX)
Competitive Landscape
HeartBeam Inc. faces competition from large, established medical device companies with broad product portfolios and significant market presence. Its competitive advantage is its specialized, AI-driven approach to early cardiac event detection, which could differentiate it from traditional methods. However, its lack of a commercialized product presents a significant disadvantage.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily in terms of R&D progress, team expansion, and securing funding to advance its technology. The company has been building its intellectual property portfolio and progressing through its development pipeline.
Future Projections: Future growth projections are contingent upon successful product development, regulatory approvals, and market adoption. Analyst estimates, if available, would typically focus on potential future revenue streams once the product is commercialized.
Recent Initiatives: Recent initiatives likely focus on advancing its platform through clinical validation, seeking regulatory clearance, and preparing for commercialization. Strategic partnerships and collaborations are also key areas of focus.
Summary
HeartBeam Inc. is a pre-revenue medical technology company with a promising AI-driven platform for cardiovascular diagnostics. Its strength lies in its innovative technology and focus on a critical unmet need in healthcare. However, significant hurdles remain, including the need for substantial funding, regulatory approvals, and market adoption. Success is contingent on effectively navigating these challenges and demonstrating clinical and commercial viability against well-established competitors.
Similar Stocks
Sources and Disclaimers
Data Sources:
- HeartBeam Inc. Investor Relations website
- SEC Filings (e.g., 10-K, 10-Q)
- Industry reports on cardiovascular diagnostics
- Financial data aggregators
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. It is not investment advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Market share data is illustrative and based on general industry estimates. Specific competitor market shares for HeartBeam's niche may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heartbeam Inc
Exchange NASDAQ | Headquaters Santa Clara, CA, United States | ||
IPO Launch date 2021-11-11 | CEO, Chief Business Officer & Director Mr. Robert P. Eno | ||
Sector Healthcare | Industry Health Information Services | Full time employees 16 | Website https://www.heartbeam.com |
Full time employees 16 | Website https://www.heartbeam.com | ||
HeartBeam, Inc. operates as a medical technology company that focuses on developing and commercializing ambulatory electrocardiogram solutions that enable the detection and monitoring of cardiac disease inside and outside a healthcare facility setting. The company develops three-dimensional vector images of cardiac electrical activity. It is developing HeartBeam AIMIGo, a credit card-sized cloud-based diagnostic software systems to address heart attack detection. The company was incorporated in 2015 and is based in Santa Clara, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.